Back to Results
First PageMeta Content
Biotechnology / Emerging technologies / Clinical research / Pharmaceutical industry / Molecular biology / Gene therapy / Cell therapy / Medicines and Healthcare products Regulatory Agency / Clinical trial / Biology / Medicine / Health


Joint Research Compliance Office This is a controlled document. The master document is posted on the JRO website and any print-off of this document will be classed as uncontrolled.
Add to Reading List

Document Date: 2012-12-17 09:11:22


Open Document

File Size: 284,14 KB

Share Result on Facebook

City

London / /

Company

INTRODUCTION GTAC / /

Country

United Kingdom / /

/

Facility

Imperial College of Science / /

IndustryTerm

investigational medicinal products / gene therapy products / e.g. antisense applications / gene therapy medicinal products / /

MedicalCondition

diseases / disorders / /

MedicalTreatment

gene therapy / stem cell therapy / gene-therapy / stem cell therapies / cell therapy / /

Organization

Health Research Authority / Clothier Committee / National Research Ethics Service / College of Science / Gene Therapy Advisory Committee / Committee on the Ethics of Gene Therapy / UK national research ethics committee / European Union / Therapy and Genetic Modification Committee / Department of Health / NHS / Medicines and Healthcare products Regulatory Agency / Joint Research Compliance Office / Genetic Modification Committee / /

Person

Gary Roper / Christine Buicke / Sharon Wood / /

/

Position

Governor / Principal Investigator / Research Governance Coordinator / mediator / Director of Safety Services Tel / Chief Investigator / /

ProgrammingLanguage

EC / /

Technology

Gene Therapy / genetic engineering / cell therapy / transplantation / stem cells / RNA technologies / /

URL

http /

SocialTag